Isterian Biotech

Executive Summary

Isterian Biotech is a preclinical-stage biotechnology company pioneering a novel approach to treat fibrosis and extend healthy lifespan by removing pathological protein crosslinks from fibrotic organs. Founded in 2018 and based in San Diego, the company leverages small molecule therapeutics to target the underlying structural damage in fibrotic tissues, which currently have limited treatment options. With fibrosis affecting millions worldwide and no disease-modifying therapies for many indications, Isterian's platform addresses a significant unmet medical need. The company is currently in the preclinical phase, focusing on lead optimization and IND-enabling studies. Given the aging global population and the direct link between fibrosis and age-related decline, Isterian's dual focus on fibrosis and lifespan extension positions it uniquely in the biotech landscape. The company's progress will depend on successful fundraising and advancement of its lead candidate toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing70% success
• Q4 2026Lead Candidate Nomination60% success
• Q2 2027Preclinical Proof-of-Concept Data Release55% success